ATP抗肿瘤药物敏感性检测技术与卵巢癌临床治疗的相关性研究  

Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer

作　　者：田海梅[1] 石晓燕[1] 傅军[1] 曹冬艳[1] 张凯[2] 吴令英[2] 王金万[3] 张伟[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院肿瘤研究所肿瘤生物学检测中心,北京100021 [2]中国医学科学院中国协和医科大学肿瘤医院妇瘤科,北京100021 [3]中国医学科学院中国协和医科大学肿瘤医院内科,北京100021

出　　处：《中华肿瘤杂志》2005年第5期296-298,共3页Chinese Journal of Oncology

摘　　要：目的采用三磷酸腺苷生物荧光法(ATP TCA)对卵巢癌组织标本进行体外药敏试验,并分析其与临床疗效的相关性。方法取卵巢癌患者术后新鲜组织和腹水标本共34例,应用ATP TCA技术对9种10组化疗药物进行体外药敏试验。结果ATP TCA技术的可评价率为94.0%,敏感性为90.0%,特异性为91.7%,阳性预测值为94.7%,阴性预测值为84.6%,整体预测值为90.6%。药物体外药敏检测结果与临床资料相符率较高。结论ATP TCA体外药敏检测结果与临床治疗反应有很好的相关性,是开展肿瘤个体化化疗的一种重要的体外药物筛选方法。Objective To determine the correlation between results of ATP bioluminescence tumor chemosensitivity assay (ATP-TCA) of human ovarian cancer specimens in vitro and clinical chemo-therapeutic responses of patients. Methods Thirty-four freshly taken ovarian cancer specimens (28 cases) and ascites (6 cases) and 9 chemotherapeutic drugs were tested in vitro for cancer chemosensitivity by ATP-TCA. Results Among the 34 ovarian cancer cases, the efficacy of ATP-TCA is 94.0%, the sensitivity, the specificity, the positive and negative predicting values, and an overall predicting value in vitro and vivo were 90.0%, 91.7%, ~94.7% ,~84.6% and 90.6%, respectively. Conclusion The results of ATP-TCA assay are correlated well with clinical treatment responses. The assay may be an important and useful method for individual-based chemotherapy of cancers.

关 键 词：ATP 抗肿瘤药物敏感性 检测技术 卵巢癌 治疗 

分 类 号：R737.31[医药卫生—肿瘤]